公开(公告)号：US20250132007A1

公开(公告)日：2025-04-24

申请号：US18909496

申请日：2024-10-08

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Ashutosh ZADE ,  Yibin ZHENG ,  Jason O’CONNOR

IPC: G16H20/17 ,  A61M5/142 ,  A61M5/172

Abstract: A medicament delivery system, process and techniques are provided. The medicament delivery system may include a wearable medicament delivery device, a memory storing programming instructions, and a processor. The processor may be operable to execute the programming instructions, which cause the processor to receive an available medicament delivery history of a user, and determine whether the available medicament delivery history spans an extent of time greater than a first glucose history duration. The processor, in response to a determination that the extent of time spanned by the available medicament delivery history is greater than the first glucose history duration, determines an average daily medicament delivered. The processor calculates a trust value of the available medicament delivery history, and utilizes the trust value to determine a total daily medicament value of the user.

公开(公告)号：US20250050021A1

公开(公告)日：2025-02-13

申请号：US18797048

申请日：2024-08-07

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  William WHITELEY ,  Jason O’CONNOR

IPC: A61M5/172 ,  G16H20/17

Abstract: Exemplary embodiments may configure the glucose cost component of a cost function used in determining basal insulin delivery doses to be limited by the maximum physiological rate of glucose level change over a time period so that the cost function more accurately reflects the physical limits of change due to insulin action, As a result, the glucose cost component of the cost function may more accurately reflect the response of a user to basal insulin deliveries, resulting in better insulin control for the user. Exemplary embodiments may modify the aggressiveness of a control approach based on a current target glucose level versus a nominal target glucose level for which the control approach was designed.

公开(公告)号：US20240325640A1

公开(公告)日：2024-10-03

申请号：US18618579

申请日：2024-03-27

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  John D’ARCO ,  Yibin ZHENG ,  Jason O’CONNOR

IPC: A61M5/172 ,  G16H20/17

CPC classification number: A61M5/1723 ,  G16H20/17

Abstract: A drug delivery system including a memory storing programming code operable to control delivery of a drug, a user interface operable to accept an input indicating a perceived glucose state of a user, and a processor operable to execute the programming code. When executed, the programming code causes the processor to: receive a perceived state signal from the user interface indicating the perceived glucose state of the user, evaluate the perceived glucose state of the user indicated by the perceived state signal using a glucose measurement value corresponding in time to when the perceived state signal was received, determine an adjustment to a drug delivery algorithm, and utilize the adjustment in a determination of a drug delivery dosage to be administered to a user.

公开(公告)号：US20240252751A1

公开(公告)日：2024-08-01

申请号：US18629121

申请日：2024-04-08

Applicant: INSULET CORPORATION

Inventor： Jason O’CONNOR ,  Joon Bok LEE ,  Trang LY ,  Todd VIENNEAU ,  Yibin ZHENG ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61K38/28 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61K38/28 ,  A61M5/14248 ,  A61M2005/14252 ,  A61M2205/18 ,  A61M2205/3553 ,  A61M2205/3584 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2230/201 ,  A61M2230/63

Abstract: A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and/or a detected location of the user.

公开(公告)号：US20240157053A1

公开(公告)日：2024-05-16

申请号：US18498275

申请日：2023-10-31

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  John D’ARCO ,  Yibin ZHENG ,  Jason O’CONNOR ,  James CAUSEY ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61M5/142 ,  G16H20/17

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  G16H20/17 ,  A61M2005/1401 ,  A61M2005/1726

Abstract: Invasive glucose sensors and noninvasive glucose sensors may be used in conjunction to improve glucose management for a user. The rate of change (ROC) of glucose levels from a noninvasive glucose sensor may be used rather than or in conjunction with a glucose level of the user from a CGM. A basal insulin delivery rate to the user may be adjusted responsive to the ROC glucose level data from the noninvasive sensor. The glucose level ROC from a noninvasive glucose sensor may be used to predict future glucose level ROCs of the user between operational cycles of an insulin delivery device and/or to identify possible hypoglycemic or hyperglycemic events. These predicted future glucose level ROCs may be used in a cost function of the control system of the insulin delivery device to select basal insulin delivery doses. Glucose level readings may be used to calibrate a noninvasive glucose level sensor.

公开(公告)号：US20230402149A1

公开(公告)日：2023-12-14

申请号：US18199638

申请日：2023-05-19

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  William WHITELEY ,  Saeed SALAVATI ,  Yibin ZHENG ,  Mert SEVIL ,  Jason O’CONNOR

IPC: G16H20/17 ,  A61B5/145 ,  A61B5/00

CPC classification number: G16H20/17 ,  A61B5/7275 ,  A61B5/14532

Abstract: Exemplary embodiments may provide for the switching of glucose prediction models responsive to certain conditions. For example, glucose prediction models may be switched responsive to a detected crashing glucose level condition. Exemplary embodiments also may dynamically customize parameters, such as coefficient values, of the glucose prediction model to a user. The exemplary embodiments may customize the glucose prediction model based on the history of glucose levels of the user and the history of insulin deliveries to the user. The exemplary embodiments may determine a set of parameters that provides an improved fit of the parameters to the history of glucose levels and insulin deliveries of the user. The improved fit parameters may be used to adapt the parameter set to the most recent run.